Having become an official partner of Prostate Cancer UK in 2009, Pentel has raised over £600,000 for the charity.
This figure has been reached through the sales of over 2.4 million special edition pens produced by Pentel. Initially supporting the charity through sales of a stylish blue barrelled ballpoint pen called LineStyle, Pentel now raises money through the best-selling product by far, EnerGel Xm Retractable.
EnerGel contains quick-drying ink to reduce smudging on hands and paper, making it ideal for both right and left-handed writers. Together with its smooth flowing EnerGel ink, it has a white barrel trimmed with light blue accents to reflect the charity’s key brand colour. For each EnerGel pen purchased, Pentel makes a donation of £0.25 to Prostate Cancer UK.
Marketing Manager, Wendy Vickery said, “sadly, prostate cancer has become the third biggest cancer killer in the UK, so it’s important to continue to support the excellent work of Prostate Cancer UK. Donations help fund important projects to raise awareness of the disease and help improve the quality of life for all the dads, brothers, sons and friends living with a diagnosis.
“Of course, none of this is achievable without the continued help and enthusiasm of our customers, which gives us the confidence to set future fundraising goals to raise even more money for Prostate Cancer UK over the coming years - next goal, £1 million.”
In the UK, over 47,000 men are diagnosed with prostate cancer every year, that’s 129 men every day. That means around 1 in 8 men will develop prostate cancer at some point in their life.
Jon Eserin, Director of Fundraising at Prostate Cancer UK added, “we have been overwhelmed by the support from Pentel and the incredible amount of money that they have raised for Prostate Cancer UK. The money raised will help fund vital research and support for men and their families facing a diagnosis.
“One man dies every 45 minutes from prostate cancer, a shocking statistic. The support from Pentel and their customers means that we are able to continue to help stop prostate cancer from being a killer, and for this, we cannot thank them enough.”